Latest Capital Raise News

Miramar Resources is launching its first drilling campaign since 1964 at the Chain Pool Project’s Joy Helen prospect, targeting high-grade SEDEX copper-lead-silver mineralisation with promising strike extensions.

Tungsten Mining has kicked off on-site preparations for a major drilling campaign at Mt Mulgine, aiming to significantly expand its tungsten resource and potentially define the world's largest deposit.

MetalsGrove Mining has defined two extensive gold anomalous trends at its Fifty-Five Prospect in Côte d’Ivoire, setting the stage for infill sampling and auger drilling during the upcoming wet season.

Genmin has drawn strong international interest to finance its Baniaka iron ore project in Gabon, with proposals ranging from joint ventures to prepayment facilities. The Gabonese government backs the project as a national priority, aiming for a final investment decision by mid-2026.

Barramundi Limited outperformed the S&P/ASX200 in April with a 4.4% gross return, boosted by NEXT DC’s landmark data centre deal and capital raise, while healthcare stocks faced headwinds from Cochlear’s profit downgrade.

Pacific Edge has raised NZ$25.4 million through an oversubscribed placement priced at NZ$0.17 per share, aiming to bolster operations, support Medicare re-coverage efforts, and advance its bladder cancer diagnostic tests.

Tartana Minerals revises its corporate presentation to clarify prior disclosures while spotlighting a $4.5 million capital raise to boost copper sulphate production and expand drilling across its Far North Queensland portfolio.

Zimi Limited has increased its placement commitments by A$100,000 from a sophisticated investor, bringing total funds raised to A$1.56 million ahead of shareholder approval.

Ballymore Resources launches a $3.24 million pro-rata entitlement offer priced at 12.5 cents per share, sweetened with free attaching options exercisable at 22 cents, to fund ongoing Queensland exploration and development.

Diablo Resources has completed the first tranche of a placement, raising $764,400 through 58.8 million shares at 1.3 cents each, with a shareholder meeting planned in June to approve a further $2.7 million raise.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

Evion Group has secured an exclusive option to acquire a high-grade fluorspar project in Nevada, complementing its graphite assets and supported by a $6.5 million capital raise to fund US expansion and exploration.